Cornerstone Robotics, a leading Chinese innovator in surgical robotics, has announced the completion of an oversubscribed USD 200 million financing round, marking one of the largest private fundraises in Asia’s medical robotics sector this year.

The round was led by Hong Kong Investment Corporation (HKIC), together with a global strategic investor and a top-tier sovereign wealth fund, joined by returning investors including Qiming Venture Partners, Bridgeone Capital, Gaorong Ventures, and K2VC.

The proceeds will be used to accelerate commercialization in China and overseas markets, as well as to advance next-generation product development and clinical registration.

Strategic Capital and Policy Endorsement from Hong Kong

HKIC’s participation holds special significance. As Hong Kong’s government-backed long-term capital investor, HKIC focuses on cross-cycle, cross-generation, and cross-border enterprises that can strengthen Hong Kong’s innovation ecosystem and global competitiveness.

Cornerstone Robotics — founded and headquartered in the Greater Bay Area — represents the region’s new generation of homegrown deep-tech innovators. HKIC’s lead investment serves as a strong policy and market endorsement of the company’s global commercialization capabilities and long-term growth potential, reaffirming Hong Kong’s commitment to nurturing next-generation technology leaders in healthcare robotics.

Global Strategic Partnerships and Expanded Market Reach

The addition of a global strategic investor and a sovereign wealth fund highlights Cornerstone’s growing international footprint. The new partners are expected to support market entry and regional collaborations in key overseas territories, driving synergy across clinical access, distribution, and academic cooperation.

The continued participation of top institutional investors underscores sustained confidence in Cornerstone’s technical roadmap, commercialization progress, and long-term value creation.

Commercial and Clinical Progress

Since its founding in 2019, Cornerstone Robotics has evolved into a unicorn in China’s surgical robotics industry. Its flagship product, the Sentire® Surgical System, has received NMPA approval and is now in clinical use across leading hospitals in mainland China, Hong Kong, and Europe.

Leveraging its full-stack in-house development and integration capabilities, the company is building a global ecosystem of intelligent surgical technologies. Cornerstone also partners with top-tier international medical and educational institutions to advance clinical training, demonstration, and academic exchange — contributing to the global accessibility of robotic-assisted surgery.

Executive Perspectives

“This round represents a defining milestone in Cornerstone’s journey,” said Professor Guowei Ou, Founder and CEO of Cornerstone Robotics. “The strong support from HKIC and our global partners demonstrates not only confidence in our innovation but also recognition of Hong Kong’s strategic role in driving the future of surgical robotics. We remain committed to delivering high-quality, accessible robotic surgery solutions to patients around the world.”

Ms. Clara Chan, CEO of Hong Kong Investment Corporation, commented: “Cornerstone Robotics exemplifies a Hong Kong-born, Bay Area-based, and globally minded medical technology company. Its mission to make surgical robotics accessible, applicable, and affordable aligns perfectly with HKIC’s ‘3A’ vision. We believe Cornerstone will serve as a flagship for Hong Kong’s innovation capacity and bring Hong Kong ingenuity to the global medical stage.”

By MedChina, November 9, 2025